Lake Street resumed coverage on Strata Critical Medical with a new price target
$SRTA
Transportation Services
Consumer Discretionary
Lake Street resumed coverage of Strata Critical Medical with a rating of Buy and set a new price target of $8.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $8.00 | Buy | Lake Street |
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will be pr
$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditionsOwned aircraft excluded from collateral package and remain unencumbered NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, "Strata" or the "Company")), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30.0 million, which, subject to certain conditions, may be increased up to an aggregate
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Strata Critical Medical, Inc. ("Strata" or the "Company"), a leading provider of logistics and medical services in the organ transplant industry, today announced the appointment of Will Cook to the Board, effective December 3, 2025. Mr. Cook has also been appointed to the Compensation and Nominating and Corporate Governance Committees. Mr. Cook is the President and Chief Executive Officer of Vail Health, a nonprofit community health care system headquartered in Vail, Colorado. "We are very excited to welcome Will Cook to our board of directors," said Melissa Tomkiel, Strata's Co-Chief Executive Office
8-K - Strata Critical Medical, Inc. (0001779128) (Filer)
8-K - Strata Critical Medical, Inc. (0001779128) (Filer)
8-K/A - Strata Critical Medical, Inc. (0001779128) (Filer)
5 - Strata Critical Medical, Inc. (0001779128) (Issuer)
4 - Strata Critical Medical, Inc. (0001779128) (Issuer)
4 - Strata Critical Medical, Inc. (0001779128) (Issuer)
4 - Strata Critical Medical, Inc. (0001779128) (Issuer)
4 - Strata Critical Medical, Inc. (0001779128) (Issuer)
Lake Street resumed coverage of Strata Critical Medical with a rating of Buy and set a new price target of $8.00
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Strata Critical Medical, Inc. ("Strata" or the "Company"), a leading provider of logistics and medical services in the organ transplant industry, today announced the appointment of Will Cook to the Board, effective December 3, 2025. Mr. Cook has also been appointed to the Compensation and Nominating and Corporate Governance Committees. Mr. Cook is the President and Chief Executive Officer of Vail Health, a nonprofit community health care system headquartered in Vail, Colorado. "We are very excited to welcome Will Cook to our board of directors," said Melissa Tomkiel, Strata's Co-Chief Executive Office
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will be pr
Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year periodMedical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition(1)Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025(1)Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA rangeInvestor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 1
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical. (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the third quarter ended September 30, 2025 on Monday, November 10, 2025 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will b